Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III study of alpha-1 antitrypsin intravenous for treatment of actue graft-versus-host disease: Combined study for USA and Europe

Next Previous
X
Search
Trial Profile

Phase II/III study of alpha-1 antitrypsin intravenous for treatment of actue graft-versus-host disease: Combined study for USA and Europe

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Graft-versus-host disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kamada

    • Most Recent Events

    • 12 Feb 2019 According to a Kamada media release, enrollment is progressing well at five active sites and the company anticipates the completion of enrolment followed by the availability of interim data from this study by the end of 2019.
    • 12 Feb 2019 Status changed from planning to recruiting, according to a Kamada media release.
    • 04 Jan 2018 According to a Kamada media release, the study will be initiated in the first quarter of 2018. The Principal Investigator of the study is John Levine. Top-line results from this study are expected to be available in the second half of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top